View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 1, 2020

Thermo Fisher Scientific launches quality control for Covid-19 tests

Thermo Fisher Scientific has launched AcroMetrix Coronavirus 2019 (Covid-19) RNA Control to monitor and validate Covid-19 molecular diagnostic tests.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.


Thermo Fisher Scientific has launched AcroMetrix Coronavirus 2019 (Covid-19) RNA Control to monitor and validate Covid-19 molecular diagnostic tests.

The new quality control product is developed by formulating synthetic RNA transcripts that contain unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into a proprietary buffer.

Thermo Fisher’s latest product launch is aimed at fighting the coronavirus outbreak.

As necessary for the test, the RNA is set for reverse transcription, PCR amplification and detection.

The kit contains two SARS-CoV-2 specific RNA vials at the concentration that will result in low-positive and ultra-low positive in commonly used Covid-19 nucleic acid testing methods that are based on Polymerase Chain Reaction (PCR).

Thermo Fisher speciality diagnostics business senior vice-president and president Gianluca Pettiti said: “Our team is committed to providing innovative solutions to support our customers with better diagnostic tools.

“The AcroMetrix Coronavirus 2019 (Covid-19) RNA Control is a positive control to aid in validating and monitoring Covid-19 diagnostic tests.”

The new RNA control is available as a Research Use Only (RUO) product globally and is not intended for clinical use.

Last month, the company announced that it expects to produce up to five million testing kits during April, to detect nucleic acid from the SARS-CoV-2 virus that causes Covid-19 disease.

Currently, the company has 1.5 million tests available to ship under the emergency use authorisation (EUA) label.

The test runs on Applied Biosystems TaqPath Assay technology and delivers patient results within four hours from when a lab receives a sample.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network